nach oben

PharmacoEconomics

Erschienen in:

01.09.2016 | Editorial

Model Validation: Has it’s Time Come?

verfasst von: Jonathan Karnon

Erschienen in: PharmacoEconomics | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Excerpt

There is broad agreement that effort should be made to validate cost-effectiveness models. The International Society for Pharmacoeconomics and Outcomes Research–Society for Medical Decision Making (ISPOR–SMDM) Modeling Good Research Practices Task Force considered model validation to be ‘vital’, while recognising that it is “not possible to specify criteria that a model must meet to be declared “valid”” [1] (page 736). …

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–43.CrossRefPubMed

National Institute for Health and Care Excellence (NICE). Single technology appraisal: user guide for company evidence submission template. January 2015 Available at: https://www.nice.org.uk/article/pmg24/chapter/5-Cost-effectiveness. Accessed 23 May 2016

Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.

Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.5). Australian Government Department of Health. 2015.

de Boer PT, Frederix GW, Feenstra TL, Vemer P. Unremarked or unperformed? Systematic review on reporting of validation efforts of health economic decision models in seasonal influenza and early breast cancer. Pharmacoeconomics. 2016. (Epub ahead of print)

Afzali HHA, Gray J, Karnon J. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases. a review and suggested reporting framework. Appl Health Econ Health Policy. 2013;11:85–93.CrossRef

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50.CrossRefPubMed

Vemer P, Ramos IC, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34:349–61.CrossRefPubMed

Titel: Model Validation: Has it’s Time Come?
verfasst von: Jonathan Karnon
Publikationsdatum: 01.09.2016
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 9/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-016-0415-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence

Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland

Economic Evaluations of Opioid Use Disorder Interventions